TOP HEADLINES

Featured Story

NIH expands vaccine clinical trial network

Over their 50-year history, the National Institutes of Health's (NIH) Vaccine and Treatment Evaluation Units (VTEUs) have shaped immunization policy by stepping up when industry can't--or won't--run trials. This week, NIH reiterated its belief in the model by expanding its network.

CDC reports across-the-board rises in flu vaccine uptake

While the government shutdown has cast doubt on the Centers for Disease Control and Prevention's (CDC) ability to manage the upcoming flu season, officials can take some solace from last year's efforts. Flu vaccine uptake levels in adults, kids and health workers all trended upward last year.

Researchers highlight knowledge gaps hindering cancer vaccines

As the succession of late-phase cancer vaccine flops shows, critical gaps in knowledge of the disease remain. Failure to tackle these gaps in breast cancer could see the loss of around 185,000 lives in the United Kingdom by 2030.

Roche targets cancer vaccine partnerships

The interest in vaccine deals stems from a belief that tweaking the immune system can have a major impact on cancer care.

European prices reapply old pressures to vaccine makers

The vaccine sector appears to be in good health. After coming through a period in which low profit margins and liability concerns deterred investment, EvaluatePharma now tips the sector to grow from $25 billion to $39 billion between 2012 and 2018. Yet, in some areas, old complaints can still be heard.

MORE NEWS

From Our Sister Sites

FierceMarkets Network
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceBiomarkers
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaManufacturing
  • FierceCRO
  • FierceDiagnostics
  • More Fierce Network sites
FierceMedicalDevices
Boreal Genomics raises $18M to support Dx test and genomic tool expansion

California's Boreal Genomics pulled in an $18 million Series C financing to back further commercial growth of its genomic research tools and diagnostic test business. The company sells research tools and develops diagnostic tests focused on noninvasive tumor profiling and cancer monitoring.

FierceDiagnostics
Boreal Genomics pulls in $18M Series C for genomic research and Dx test expansion

California's Boreal Genomics pulled in an $18 million Series C financing to back further commercial growth of its genomic research tools and diagnostic test business.